Results 201 to 210 of about 462,486 (334)

Insights into human history and complex traits from the genomes of African populations. [PDF]

Mol Biol Evol
Bitsue HK, Tang C, Yang Z.
europepmc   +1 more source

Love of the Job: What It Is, How to Measure It, and Why It Matters for Work Outcomes

Human Resource Management, EarlyView.
ABSTRACT Employee retention, motivation, performance, and well‐being remain enduring priorities in human resource management, yet existing constructs such as engagement, commitment, and satisfaction do not fully capture the depth of emotional attachment that some employees feel towards their jobs.
Michelle Inness, Kaylee Somerville, Zhanna Lyubykh, Nick Turner, E. Kevin Kelloway, Julian Barling, Lori Francis, Laure E. Pitfield, Constance E. Bygrave   +8 more
wiley   +1 more source

Repeated induced abortion among women seeking abortion care services in public health facilities in Harar town, Eastern Ethiopia. [PDF]

Sci Rep
Mustefa A, Mezmur H, Abdurahman D, Adem HA, Usso AA.   +4 more
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Mapping a Decade of Osteoporosis and Fracture Research: A Bibliometric Analysis (2015-2025). [PDF]

J Bone Metab
Balogun OS, Olaleye SA, Balogun MA, Olaleye EO, Arshad MZ, Haataja K, Toivanen P.   +6 more
europepmc   +1 more source

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

International Journal of Cancer, EarlyView.
What's New? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner, Gerd Grözinger, Jörg Schmehl, Lukas Flatz, Andrea Forschner   +4 more
wiley   +1 more source

A global media scan on plastic waste using Tobacco Watcher: Opportunities for tobacco control. [PDF]

Tob Induc Dis
Kennedy RD, Walker EK, Kaur H, Welding K.   +3 more
europepmc   +1 more source

Women in the Department of Middle Eastern Languages and Cultures

, 2023
openaire   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

International Journal of Cancer, EarlyView.
What's New? Although patients with melanoma brain metastases (MBM) may benefit from treatment with immune checkpoint inhibitors (ICIs), which are known to improve survival in advanced melanoma, MBM patients have often been excluded from trials evaluating ICIs.
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, Peter Mohr, Thomas Sickmann, Pia Dücker, Christoffer Gebhardt, Sebastian Haferkamp, Katharina C. Kähler, Friedegund Meier, Claudia Pföhler, Anca Sindrilaru, Patrick Terheyden, Imke von Wasielewski, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Dirk Schadendorf   +18 more
wiley   +1 more source